A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers
Latest Information Update: 09 May 2025
At a glance
- Drugs OP-801 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Ashvattha Therapeutics
Most Recent Events
- 02 May 2025 Planned End Date changed from 1 Mar 2025 to 1 May 2026.
- 02 May 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
- 13 Jan 2025 According to an Ashvattha Therapeutics media release, the company has announced additional financing as an extension of its Series B of up to $50 million led by Tribe Capital with existing investors led by Natural Capital. The funding will enable company to complete this trial.